Literature DB >> 2243107

Apolipoprotein B messenger RNA editing is developmentally regulated and widely expressed in human tissues.

B Teng1, M Verp, J Salomon, N O Davidson.   

Abstract

Apolipoprotein B (apoB) messenger RNA (mRNA) undergoes posttranscriptional (C to U) editing, producing tissue-specific forms of apoB from the unedited (apoB100) and edited (apoB48) transcripts. ApoB mRNA editing is developmentally regulated in human fetal small intestine, producing parallel changes in the synthesis and secretion of apoB100 and apoB48. Neither fetal nor adult liver contained detectable levels (less than 1%) of edited apoB mRNA. By contrast, apoB mRNA is incrementally edited during development in several extraintestinal fetal tissues. These tissues demonstrated significant differences, however, in both the extent and developmental profile of apoB mRNA editing. Additionally, while apoB100 synthesis and secretion was demonstrated in these tissues, apoB48 synthesis was confined to the small intestine. Thus, although the molecular mechanism underlying this process remains unclear, the capacity to edit apoB mRNA is widely distributed among both fetal and adult tissues. We speculate that the asynchronous and developmentally modulated induction of apoB mRNA editing may provide a novel mechanism for regulating lipoprotein biogenesis in both the developing fetus and adult human.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2243107

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Escherichia coli sepsis increases hepatic apolipoprotein B secretion by inhibiting degradation.

Authors:  H W Phetteplace; N Sedkova; K I Hirano; N O Davidson; S P Lanza-Jacoby
Journal:  Lipids       Date:  2000-10       Impact factor: 1.880

2.  Increased expression of apolipoprotein genes accompanies differentiation in the intestinal cell line Caco-2.

Authors:  S R Reisher; T E Hughes; J M Ordovas; E J Schaefer; S I Feinstein
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

3.  RNA editing of a group II intron in Oenothera as a prerequisite for splicing.

Authors:  G V Börner; M Mörl; B Wissinger; A Brennicke; C Schmelzer
Journal:  Mol Gen Genet       Date:  1995-03-20

Review 4.  APOBEC-1-mediated RNA editing.

Authors:  Valerie Blanc; Nicholas O Davidson
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2010 Sep-Oct

Review 5.  Insights from human congenital disorders of intestinal lipid metabolism.

Authors:  Emile Levy
Journal:  J Lipid Res       Date:  2014-11-11       Impact factor: 5.922

6.  Enzymological and mutational analysis of a complex primary hyperoxaluria type 1 phenotype involving alanine:glyoxylate aminotransferase peroxisome-to-mitochondrion mistargeting and intraperoxisomal aggregation.

Authors:  C J Danpure; P E Purdue; P Fryer; S Griffiths; J Allsop; M J Lumb; K M Guttridge; P R Jennings; J I Scheinman; S M Mauer
Journal:  Am J Hum Genet       Date:  1993-08       Impact factor: 11.025

7.  Molecular cloning of a human small intestinal apolipoprotein B mRNA editing protein.

Authors:  C Hadjiagapiou; F Giannoni; T Funahashi; S F Skarosi; N O Davidson
Journal:  Nucleic Acids Res       Date:  1994-05-25       Impact factor: 16.971

8.  Insulin promotes the biosynthesis and secretion of apolipoprotein B-48 by altering apolipoprotein B mRNA editing.

Authors:  F E Thorngate; R Raghow; H G Wilcox; C S Werner; M Heimberg; M B Elam
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

9.  APOBEC1 complementation factor (A1CF) is dispensable for C-to-U RNA editing in vivo.

Authors:  Elizabeth M Snyder; Christopher McCarty; Adrienne Mehalow; Karen L Svenson; Stephen A Murray; Ron Korstanje; Robert E Braun
Journal:  RNA       Date:  2017-01-09       Impact factor: 4.942

Review 10.  From Congenital Disorders of Fat Malabsorption to Understanding Intra-Enterocyte Mechanisms Behind Chylomicron Assembly and Secretion.

Authors:  Emile Levy; Jean François Beaulieu; Schohraya Spahis
Journal:  Front Physiol       Date:  2021-01-27       Impact factor: 4.566

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.